Literature DB >> 31460706

Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder.

Takako Shiota1, Kazumasa Torimoto2, Masahiro Okuda3, Ryo Iwata4, Hiromi Kumamoto5, Makito Miyake2, Akihide Hirayama6, Nobumichi Tanaka2, Kiyohide Fujimoto2.   

Abstract

This study aimed to investigate the cognitive burden and polypharmacy in elderly patients treated with anticholinergics for an overactive bladder. We conducted a retrospective study of patients with an overactive bladder receiving treatment at two hospitals in Japan (Nara Medical University Hospital and Saiseikai Nara Hospital). Prescription data were collected from the medical records of the patients registered between January 2013 and April 2014. The Anticholinergic Cognitive Burden Scale was used to estimate the severity of the anticholinergic effects on the cognition of each patient. We collected the prescription data of 584 and 246 patients from the Nara Medical University Hospital and Saiseikai Nara Hospital, respectively. The mean daily total Anticholinergic Cognitive Burden score ranged between 3 and 4 (3.59 ± 1.16 at Nara Medical University Hospital vs 3.32 ± 0.78 at Saiseikai Nara Hospital, P < 0.01). At both hospitals, the mean number of prescriptions was >5 in patients ≥75 years (5.95 ± 4.43 and 5.64 ± 3.90 at Nara Medical University Hospital and Saiseikai Nara Hospitals, respectively). Our findings suggest that 10%-20% of elderly patients (≥65 years) receiving treatment with anticholinergics for an overactive bladder are in a state of polypharmacy. The total anticholinergic cognitive burden of each patient mainly depends on the anticholinergics being used for treating the overactive bladder. Especially for elderly patients with a high risk of adverse effects, including cognitive impairment, careful attention needs to be paid during selection of drugs for treating patients with an overactive bladder.
© 2019 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  anticholinergics; cognition; elderly; overactive bladder; polypharmacy

Mesh:

Substances:

Year:  2019        PMID: 31460706     DOI: 10.1111/luts.12285

Source DB:  PubMed          Journal:  Low Urin Tract Symptoms        ISSN: 1757-5664            Impact factor:   1.592


  3 in total

1.  Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats.

Authors:  Peng Sun; Zheng Wang; Tong Wu; Shishuai Zuo; Xiaoyu Huang; Zilian Cui; Dong Zhang
Journal:  Front Bioeng Biotechnol       Date:  2022-06-27

2.  Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).

Authors:  Hiroshi Nakagomi; Takahiko Mitsui; Hiroshi Shimura; Tatsuya Ihara; Satoru Kira; Norifumi Sawada; Masayuki Takeda
Journal:  BMC Urol       Date:  2022-03-21       Impact factor: 2.090

3.  Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome.

Authors:  Martin Taylor-Rowan; Sophie Edwards; Anna H Noel-Storr; Jenny McCleery; Phyo K Myint; Roy Soiza; Carrie Stewart; Yoon Kong Loke; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2021-05-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.